Population pharmacokinetics of fusidic acid: Rationale for front-loaded dosing regimens due to autoinhibition of clearance

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 498-507

  Bulitta, Jürgen B ^a,c   Okusanya, Olanrewaju O ^b,c   Forrest, Alan ^b,c   Bhavnani, Sujata M ^b,c   Clark, Kay ^d   Still, J Gordon ^d   Fernandes, Prabhavathi ^d   Ambroseb, Paul G ^b,c,e  

^a MONASH UNIVERSITY   (Australia)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Cempra Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDATE SODIUM; PLACEBO;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; FOLLOW UP; FOOD DRUG INTERACTION; HUMAN; IC 50; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TURNOVER TIME;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD; FUSIDIC ACID; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872024013     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01354-12     Document Type: Article

References (32)

1. Carr WD, Wall AR, Georgala-Zervogiani S, Stratigos J, Gouriotou K. 1994. Fusidic acid tablets in patients with skin and soft-tissue infection: a dose-finding study. Eur. J. Clin. Res. 5:87-95.
2. Goncalves J, Thorn P. 1991. Fusidic acid and the treatment of patients with skin and soft tissue infections. Eur. J. Clin. Res. 1:91-97.
3. Morris CDE, Talbot DT. 2000. A comparison of fusidic acid tablets and flucloxacillin capsules in skin and soft tissue. J. Drug Assess. 3:33-46.
4. Nordin P, Mobacken H. 1994. A comparison of fusidic acid and flucloxacillin in the treatment of skin and soft-tissue infection. Eur. J. Clin. Res. 5:97-106.
5. Craft JC, Moriatry SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P. 2011. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin. Infect. Dis. 52(Suppl 7):S520-526.
6. Still JG, Clark K, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ. 2011. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin. Infect. Dis. 52(Suppl 7):S504-S512.
7. Godtfredsen WO, Vangedal S. 1966. On the metabolism of fusidic acid in man. Acta Chem. Scand. 20:1599-1607.
8. Reeves DS. 1987. The pharmacokinetics of fusidic acid. J. Antimicrob. Chemother. 20:467-476.
9. Brown NM, Reeves DS, McMullin CM. 1997. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. J. Antimicrob. Chemother. 39:803-809.
10. Peter JD, Jehl F, Pottecher T, Dupeyron JP, Monteil H. 1993. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob. Agents Chemother. 37:501-506.
11. Taburet AM, Guibert J, Kitzis MD, Sorensen H, Acar JF, Singlas E. 1990. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J. Antimicrob. Chemother. 25(Suppl B):23-31.
12. Munkholm P, Hey H, Rasmussen SN, Johansen PB. 1994. Antibiotic activity in serum following single and repeated oral administration of sodium fusidate in volunteers. Eur. J. Drug Metab. Pharmacokinet. 19:337-341.
13. Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L. 1962. Fusidic acid: a new antibiotic. Nature 193:987.
14. Turnidge J. 1999. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 12(Suppl 2):S23-S34.
15. Bulitta JB, Holford NHG. 2008. Non-compartmental analysis, p 1-21. In D'Agostino RB, Sullivan L, Massaro J (ed), Wiley encyclopedia of clinical trials. John Wiley & Sons, Inc., Hoboken.
16. Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F. 2009. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Antimicrob. Agents Chemother. 53:3462-3471.
17. MacGowan AP, Greig MA, Andrews JM, Reeves DS, Wise R. 1989. Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. J. Chemother. 1:593-596.
18. Karlsson MO, Sheiner LB. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750.
19. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
20. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
21. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677-1679.
22. West GB, Woodruff WH, Brown JH. 2002. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. Proc. Natl. Acad. Sci. U. S. A. 99(Suppl. 1):2473-2478.
23. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036-2049.
24. Bauer RJ. 2008. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis, Berkeley, CA.
25. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 13:212-226.
26. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211.
27. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. 2005. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br. J. Clin. Pharmacol. 59:189-198.
28. Gordi T, Xie R, Jusko WJ. 2005. Semi-mechanistic pharmacokinetic/ pharmacodynamic modelling of the antimalarial effect of artemisinin. Br. J. Clin. Pharmacol. 60:594-604.
29. Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, Sorgel F, Rodamer M, Fuhr U. 2009. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob. Agents Chemother. 53:2892-2901.
30. Plock N, Buerger C, Joukhadar C, Kljucar S, Kloft C. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816-1823.
31. Okusanya OO, Tsuji BT, Bulitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG. 2011. Evaluation of the pharmacokinetics- pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn. Microbiol. Infect. Dis. 70:101-111.
32. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG. 2011. Application of pharmacokinetics-pharmacodynamic modeling and the justification of novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin. Infect. Dis. 52(Suppl 7):S513-S519.